Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension
Thomas E Serena, Vincent Brandenburg, Dinesh K. Chatoth, Jeffrey L. Hymes et al.
Citations
17 citations
Journal
EClinicalMedicine
Topics
Parathyroid Disorders and Treatments
Field-Weighted Citation Impact (FWCI)
5.77
article
Hexasodium fytate for the treatment of calciphylaxis: a randomised, double-blind, phase 3, placebo-controlled trial with an open-label extension
Thomas E Serena, Vincent Brandenburg, Dinesh K. Chatoth, Jeffrey L. Hymes, Glenn M. Chertow, Sagar U. Nigwekar, Joan Perelló, Gabriela Alperovich, Sharon M. Moe, Smeeta Sinha, Lisa J. Gould, Kevin J. Carroll, L Keller, George R. Aronoff, Alex Gold
article en
17 citations
Abstract
No abstract available for this paper.
Publication Tag
EClinicalMedicineVol. 75
Institutions
Harvard University (US), Manchester Academic Health Science Centre (GB), Salford Royal NHS Foundation Trust (GB), Sierra Nevada College (US), University of Manchester (GB), Massachusetts General Hospital (US), South Shore Hospital (US), KCI (Ireland) (IE), Salford Royal Hospital (GB), Michigan Medicine (US), VA Center for Clinical Management Research (US), SerenaGroup Research Institute (US), Fresenius Medical Care (United States) (US), Health Research Institute of the Balearic Islands (ES), Clinica Rotger (ES), Research Institute of Health Sciences (ES), Colorado Kidney Care (US), Klinikum Rheine (DE), Vifor Pharma (United States) (US), Indiana University School of Medicine, Indiana University – Purdue University Indianapolis (US), Stanford University (US)